<DOC>
	<DOCNO>NCT02842580</DOCNO>
	<brief_summary>The intensity tumour response appear correlated feasibility duration therapeutic pause reduce maintenance therapy maintain progression patient initially control so-called `` induction '' chemotherapy . Bevacizumab combine cytotoxic chemotherapy ( 5-FU , irinotecan and/or oxaliplatin ) show possible improve tumour response rate patient prognosis 1st 2nd line . With favourable safety profile , excellent candidate induction treatment also maintenance treatment . Prospective data recent trial actually demonstrate improvement PFS and/or overall survival bevacizumab maintenance alone combination 5FU ( capecitabine ) induction chemotherapy ( FOLFIRI FOLFOX + bevacizumab ) . At time , maintenance anti-angiogenic pressure progression 1st line metastatic demonstrate benefit term PFS overall survival . Bevacizumab maintenance 2nd line metastatic , despite progression , thus appear valid strategy .</brief_summary>
	<brief_title>De-escalation Chemotherapies Versus Escalation Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Thus , objective work combine continuous block angiogenesis bevacizumab give first 3 metastatic line randomise phase II trial evaluate `` descend '' strategy immediate optimisation 4 cycle FOLFOXIRI-bevacizumab 4 cycle FOLFIRI-bevacizumab , follow maintenance treatment 5FU-bevacizumab progression ( re-introduction induction case progression ) evaluate `` ascend '' strategy 5FU-bevacizumab immediately follow , progression , introduction irinotecan , oxaliplatin , maintenance block angiogenesis bevacizumab .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Metastatic colorectal cancer , histologically prove ( primary tumour and/or metastasis ) Unresectable nonpretreated metastasis BRAF wildtype Patient consider able receive 3 line chemotherapy At least one measurable target lesion &gt; 1 cm accord RECIST 1.1 ( Appendix 4 ) Tumour assessment accord RECIST , perform 4 week less prior randomization Age ≥ 18 year WHO performance status ≤ 2 ( Appendix 5 ) No major surgery within 4 week prior randomisation . Wound heal must complete Life expectancy great 3 month Laboratory test : Neutrophils ≥ 1500/mm3 , platelet ≥ 100,000/mm3 , haemoglobin &gt; 9 g/dL Creatinine clearance &gt; 30 mL /min ( capecitabine dose modification creatinine clearance &lt; 3050 mL/min ) , serum creatinine &lt; 1.25 x ULN Liver function test : bilirubin &lt; 1.25 x ULN , AST/ALT &lt; 5 x ULN Women childbearing age men ( sexual relation woman childbearing age ) must agree use effective contraception without interruption throughout duration treatment 6 month last administration Signed informed consent Patient potentially resectable colorectal cancer ; i.e . goal chemotherapy would make metastasis resectable Patients symptomatic metastasis Patient aggressive disease large tumour volume Active gastroduodenal ulcer , wound bone fracture At least one follow laboratory value : Neutrophils &lt; 1500/mm3 , platelet &lt; 100,000/mm3 , haemoglobin &lt; 9 g/dL , total bilirubin &gt; 1.5 N , alkaline phosphatase &gt; 2.5 N ( &gt; 5 N case hepatic involvement ) , serum creatinine &gt; 1.5 N , 24 hr proteinuria &gt; 1 g Chronic inflammatory bowel disease , extensive resection small bowel Clinically significant coronary artery disease history myocardial infraction within last 6 month . Uncontrolled hypertension receive chronic medication Abdominal major extraabdominal surgical procedure ( except diagnostic biopsy ) radiation within 4 week start treatment Previous treatment antiangiogenic irinotecan Known suspect central nervous system metastasis CNS metastasis , suspect CNS metastases Other previous malignancy within 5 year , except basal cell carcinoma skin preinvasive carcinoma cervix Peritoneal macronodular carcinomatosis History haemoptysis ≥ grade 2 ( define ≥ 2.5 mL bright red blood per episode ) month prior inclusion Known hypersensitivity component bevacizumab one study treatment Active infection require intravenous antibiotic start treatment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess active gastrointestinal bleeding within 6 month prior treatment start Pregnant breastfeed woman Concomitant participation another clinical study involve drug treatment phase 30 day start study treatment Patient unable undergo medical treatment geographical , social , psychological legal reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>metastasis</keyword>
</DOC>